StockData
Upstream Bio, Inc. logo

Upstream Bio, Inc. (UPB) company profile

UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.10−0.05 (-2.33%)

Close on Nov 17, 2026Market cap $115.02MP/E –Yield –

About Upstream Bio

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biotechnology company that focuses on developing treatments for severe inflammatory and respiratory disorders. Its primary investigational drug candidate is verekitug, a recombinant human monoclonal antibody designed to bind and inhibit the Thymic Stromal Lymphopoietin receptor. The company is advancing this product candidate across clinical programs for indications such as severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Its target patient population consists of individuals suffering from severe immune-mediated conditions underserved by current standards of care.

The company evaluates verekitug through multi-national clinical trials, having administered the drug candidate to approximately 500 trial participants across five clinical studies. In addition, its research activities include conducting Japanese ethnobridging evaluations as part of its global clinical development efforts. The provided text does not disclose the location of the company's headquarters or any operational facilities.

Summary of the business section of Upstream Bio's latest annual report, written by StockData.

Company profile

Company

Legal name
Upstream Bio, Inc.
Headquarters
Waltham, MA
Address
890 Winter Street, Suite 200 02451
Phone
(781) 208-2466
Employees
75, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
UPB
Exchange
Nasdaq
IPO date
Oct 11, 2024
Shares outstanding
55M, Aug 4, 2026
Public float
$467.86M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
2022626
CUSIP
91678A107
ISIN
US91678A1079
FIGI
BBG017Y2X923
Share class FIGI
BBG017Y2X950
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Everett Rand SutherlandChief Executive Officer, Director68,717
Aaron DeykinChief Medical Officer32,302
Allison AmbroseGeneral Counsel15,563
Michael GrayCFO and COO27,942
Adam HoughtonChief Business Officer22,901
Erez ChimovitsDirector4,554,873
Harold Edward FlemingDirector–
Liam RatcliffeDirector–
Marcella K. RuddyDirector–
Ronald C. Renaud JRDirector–
Daniella BeckmanDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
E. Rand Sutherland, M.D.
Chief Executive Officer (4)
$650.00K$3.30M$341.25K$10.50K$4.30M-53%
Michael Paul Gray, M.B.A.
Chief Financial Officer and Chief Operating Officer (5)
$490.00K$1.29M$205.80K$10.50K$1.99M-32%
Aaron Deykin, M.D.
Chief Medical Officer and Head of Research and Development (6)
$515.00K$1.09M$216.30K$10.50K$1.83M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 11, 2024
Offer price
$17.00
Securities offered
15,000,000
Gross proceeds
$255.00M
Exchange
Nasdaq
First trading day
Oct 11, 2024
First-day close
$22.00+29.4%
Lock-up ends (est.)
Apr 9, 2025

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 20, 2026, we had 75 full-time employees, 22 of which have M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?